/   Home   /   Newsroom   /   Research in China

Diabetes Drug May Help Treat Breast Cancer

Mar 21, 2017     Email"> PrintText Size

Researchers in China have discovered that a drug used to treat diabetes could be effective against a form of deadly breast cancer.

More than 70,000 people die from breast cancer in China every year, according to the national cancer center.

Triple-negative breast cancer is particularly aggressive among the four clinical subtypes of breast cancer, said Dong Chenfang, a professor at Zhejiang University School of Medicine. It has a tendency to quickly spread or metastasize to the brain and lungs. There are currently no effective targeted therapies for this form of breast cancer, which is therefore often fatal, according to Dong.8 Dong and his colleagues found that the levels of a metabolic enzyme called AKR1B1 were significantly elevated in triple-negative breast cancer cells and that this was associated with increased rates of metastasis and shorter survival times.

The researchers also found epalrestat, a drug that inhibits AKR1B1 and is approved in Japan to treat diabetic complications, was able to block the growth and metastasis of the cancer cells.

Dong said the finding is still in the experimental stage. Whether epalrestat can be applied to the clinical treatment still needs further tests.

A detailed research article was published on March 7 in the Journal of Experimental Medicine. (Xinhua)


(Editor: LIU Jia)



Related Articles

CHEK2;breast cancer;DNA damage response

Novel and Loss of Function CHEK2 Mutation Underlies Early Onset Breast Cancer in China

Jan 28, 2015

Breast cancer is the most frequently diagnosed cancer and the second leading cause for cancer death in females worldwide. DING Hongyu and his colleagues from a research group led by Prof. JIANG Hai at the Institute of Biochemistry and Cell Biology, Shanghai Institutes for...

PGAM1;PARP;breast cancer;anticancer therapy

Scientists Discover Potential Boost for Olaparib in Triple-negative Breast Cancer

Feb 22, 2017

Scientists from Shanghai Institute of Materia Medica (SIMM) of Chinese Academy of Sciences made progress in discovering the role of the metabolic enzyme phosphoglycerate mutase 1 (PGAM1) in maintaining genomic stability, and found that PGAM1 inhibitors have the potential ...

Contact Us

Copyright © 2002 - 2017 Chinese Academy of Sciences